BHVN Stock Price History and Quote Analysis: Insights for Investors
Biohaven Pharmaceutical Holding Company Ltd.
Stock Price Today
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stock surged +2.10%, trading at $47.63 on NYSE, up from the previous close of $46.65. The stock opened at $46.46, fluctuating between $46.02 and $47.82 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Company Information
| Employees | 239 |
| Beta | 4.113 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock price is $47.63 in the last trading session. During the trading session, BHVN stock reached the peak price of $47.82 while $46.02 was the lowest point it dropped to. The percentage change in BHVN stock occurred in the recent session was 2.1% while the dollar amount for the price change in BHVN stock was $0.98.
The NYSE listed BHVN is part of Biotechnology industry that operates in the broader Healthcare sector. Biohaven Pharmaceutical Holding Company Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Kimberly Gentile
Senior Vice President of Clinical Operations
Mr. John Tilton
Chief Commercial Officer of Rare Diseases
Mr. Matthew Buten
Chief Financial Officer
Mr. George C. Clark
Vice President & Chief Accounting Officer
Mr. Chris Barrett
Senior Vice President of Commercial Strategy, Common Disease
Mr. Warren Volles
Gen. Counsel & Chief Legal Officer
Mr. Clifford Bechtold M.S.
Chief Compliance Officer
Mr. Warren Volles J.D.
Gen. Counsel & Chief Legal Officer
Ms. Deb Young
Director of Regulatory Affairs & Operations
Ms. Jennifer Porcelli
Head of Investor Relations
Dr. Bruce D. Car DACVP, Ph.D.
Consultant
Dr. Vladimir Coric M.D.
Chairman & Chief Executive Officer
BHVN's closing price is 102.6% higher than its 52-week low of $23.51 where as its distance from 52-week high of $62.21 is -23.44%.
Number of BHVN employees currently stands at 239.
Official Website of BHVN is: https://www.biohavenpharma.com
BHVN could be contacted at phone 203 404 0410 and can also be accessed through its website. BHVN operates from 215 Church Street, New Haven, CT 06510, United States.
BHVN stock volume for the day was 434.16K shares. The average number of BHVN shares traded daily for last 3 months was 976.87K.
The market value of BHVN currently stands at $4.81B with its latest stock price at $47.63 and 100.95M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com